Recovery of orbital fat pad prolapsus and deepening of the lid sulcus from topical bimatoprost therapy: 2 case reports and review of the literature

Cutaneous and Ocular Toxicology

Volumn 29, Issue 3, 2010, Pages 209-213

  Aydin, Sayime ^a   Iikligil, Iil ^b   Teken, Yasemin Aktan ^a   Kir, Erkin ^b  

^a DUMLUPINAR UNIVERSITY   (Turkey)

^b ADNAN MENDERES UNIVERSITY   (Turkey)

Author keywords

adverse effects; Bimatoprost; deepening of lid sulcus; fat pad prolapsus; glaucoma

Indexed keywords

BIMATOPROST; DORZOLAMIDE PLUS TIMOLOL; AMIDE; ANTIHYPERTENSIVE AGENT; CLOPROSTENOL; DRUG DERIVATIVE;

ADULT; AGED; ARTICLE; CASE REPORT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EYE HYPERPIGMENTATION; EYELID DISEASE; GLAUCOMA; HUMAN; HYPERPIGMENTATION; MALE; MEDICAL RECORD REVIEW; OBSERVATIONAL STUDY; ORBIT DISEASE; ORBIT FAT PAD PROLAPSUS; ORBITAL FAT PAD PROLAPSUS; RETROSPECTIVE STUDY; VISUAL ACUITY; ADIPOSE TISSUE; DRUG EFFECT; EYELASH; EYELID; IRIS; MIDDLE AGED; REVIEW; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADIPOSE TISSUE; ADMINISTRATION, TOPICAL; AGED; AMIDES; ANTIHYPERTENSIVE AGENTS; CLOPROSTENOL; EYELASHES; EYELIDS; GLAUCOMA; HUMANS; IRIS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 79952199444     PISSN: 15569527     EISSN: 15569535     Source Type: Journal    
DOI: 10.3109/15569521003775013     Document Type: Article

References (15)

1. Noecker RS, Dirks MS, Choplin NT, Bernstein P, Batoosingh AL, Whitcup SM. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 2003; 135:55-63. (Pubitemid 36020425)
2. Hollo G. The side effects of the prostaglandin analogues. Expert Opin Drug Saf 2007; 6(1):45-52.
3. Aydin S, Ozcura F. Corneal oedema and acute anterior uveitis after two doses of travoprost. Acta Ophthalmol Scand 2007; 85:693-694.
4. Stjernschantz JW, Albert DM, Hu DN, Drago F, Wistrand PJ. Mechanism and clinical significance of prostaglandininduced iris pigmentation. Surv Ophthalmol 2002; 47(suppl 1):S162-S175.
5. Johnstone MA, Albert DM. Prostaglandin-induced hair growth. Surv Ophthalmol 2002; 47(suppl 1):S185-S202.
6. Peplinski LS, Albiani Smith K. Deepening of lid sulcus from topical bimatoprost therapy. Optom Vis Sci 2004; 81:574-577.
7. Yam JC, Yuen NS, Chan CW. Bilateral deepening of upper lid sulcus from topical bimatoprost therapy. J Ocul Pharmacol Ther 2009; 25:471-472.
8. Yang HK, Park KH, Kim TW, Kim DM. Deepening of eyelid superior sulcus during topical travoprost treatment. Jpn J Ophthalmol 2009; 53:176-179.
9. Sooranna SR, Grigsby P, Myatt L, Bennett PR, Johnson MR. Prostanoid receptors in human uterine myocytes: the effect of reproductive state and stretch. Mol Hum Reprod 2005; 11:859-864.
10. Tappeiner C, Perren B, Iliev ME, Frueh BE, Goldblum D. Orbital fat atrophy in glaucoma patients treated with topical bimatoprost-can bimatoprost cause enophthalmos? Klin Monatsbl Augenheilkd 2008; 225:443-445.
11. Filippopoulos T, Paula JS, Torun N, Hatton MP, Pasquale LR, Grosskreutz CL. Periorbital changes associated with topical bimatoprost. Ophthal Plast Reconstr Surg 2008; 24:302-307.
12. Steinhäuser SL. Decreased high-density lipoprotein serum levels associated with topical bimatoprost therapy. Optometry 2006; 77:177-179.
13. Casimir DA, Miller CW, Ntambi JM. Preadipocyte differentiation blocked by prostaglandin stimulation of prostanoid FP2 receptor in murine 3T3-L1 cells. Differentiation 1996; 60:203-210.
14. Sharif NA, Williams GW, Kelly CR. Bimatoprost and its free acid are prostaglandin FP receptor agonists. Eur J Pharmacol 2001; 432:211-213.
15. Woodward DF, Krauss AH, Chen J, et al. Pharmacological characterization of a novel antiglaucoma agent, bimatoprost (AGN 192024). J Pharmacol Exp Ther 2003; 305:772-785.